tiprankstipranks
Advertisement
Advertisement

NVS Stock Latest News

3 Vanguard ETFs That Pay Reliable Dividends
Market News3 Vanguard ETFs That Pay Reliable Dividends
5d ago
RY
COP
Novartis to Acquire Myricx Bio for $1.5B to Boost Cancer Drugs; NVS Stock Falls
PremiumMarket News
Novartis to Acquire Myricx Bio for $1.5B to Boost Cancer Drugs; NVS Stock Falls
8d ago
NVS
Novartis agrees to acquire Myricx Bio for up to $1.5B
PremiumThe Fly
Novartis agrees to acquire Myricx Bio for up to $1.5B
8d ago
NVS
Novartis to acquire Myricx Bio for $1.1B upfront
PremiumThe Fly
Novartis to acquire Myricx Bio for $1.1B upfront
8d ago
NVS
Novartis receives EC approval for Itvisma for spinal muscular atrophy
PremiumThe Fly
Novartis receives EC approval for Itvisma for spinal muscular atrophy
12d ago
NVS
PremiumRatingsBuy Rating Reaffirmed as Medium-Term Growth Outlook Supports Unchanged $140 Price Target
12d ago
NVS
Anthropic takes aim at pharma industry with Claude Science, STAT reports
Premium
The Fly
Anthropic takes aim at pharma industry with Claude Science, STAT reports
13d ago
AZN
BMY
Premium
Ratings
Novartis: Buy Rating Reiterated on Pelacarsen Cardiovascular Upside; $135 Price Target Unchanged
18d ago
NVS
SCHD vs. VYMI vs. JEPI: Which Is the Best Dividend ETF for Steady Passive Income?
PremiumMarket News
SCHD vs. VYMI vs. JEPI: Which Is the Best Dividend ETF for Steady Passive Income?
21d ago
NVS
HSBC
BTIG says others may be interested in Apogee Therapeutics
PremiumThe Fly
BTIG says others may be interested in Apogee Therapeutics
22d ago
JNJ
NVS
CMS proposes to lock in lower prices in Medicare drug price negotiation program
PremiumThe Fly
CMS proposes to lock in lower prices in Medicare drug price negotiation program
28d ago
AZN
BMY
Novartis announces Rhapsido met primary endpoints in RemIND trial
PremiumThe Fly
Novartis announces Rhapsido met primary endpoints in RemIND trial
1M ago
NVS
Novartis Del-brax Trial Hits Key Biomarker Goals in FSHD, Phase III Under Way
PremiumCompany AnnouncementsNovartis Del-brax Trial Hits Key Biomarker Goals in FSHD, Phase III Under Way
1M ago
6K
NVS
Premium
Ratings
Novartis Del-brax Data Bolster FSHD Outlook as Analyst Reiterates Buy and Maintains $135 Price Target
1M ago
NVS
Premium
Ratings
Novartis: Buy Rating Reiterated as Del-brax Data and Late-Stage Pipeline Support Unchanged CHF 140 Price Target
1M ago
NVS
Novartis announces biomarker cohort in study of del-brax met primary endpoint
PremiumThe Fly
Novartis announces biomarker cohort in study of del-brax met primary endpoint
1M ago
NVS
Novartis, Orionis enter collaboration for molecular glue medicines
PremiumThe Fly
Novartis, Orionis enter collaboration for molecular glue medicines
1M ago
NVS
Acting FDA head vows to block political interference, Endpoint News says
PremiumThe Fly
Acting FDA head vows to block political interference, Endpoint News says
1M ago
AZN
BMY
Novartis reports final 2.5-year Phase III ALIGN results on Vanrafia
PremiumThe Fly
Novartis reports final 2.5-year Phase III ALIGN results on Vanrafia
1M ago
NVS
FDA issues draft guidance to help accelerated cell, gene therapies for patients
PremiumThe FlyFDA issues draft guidance to help accelerated cell, gene therapies for patients
1M ago
AZN
BMY
Novartis announces 144-week data from ASC4FIRST trial of Scemblix
Premium
The Fly
Novartis announces 144-week data from ASC4FIRST trial of Scemblix
1M ago
NVS
Novartis announces results on rPFS improvements across subgroups with Pluvicto
Premium
The Fly
Novartis announces results on rPFS improvements across subgroups with Pluvicto
1M ago
NVS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >